Dr Peter Schmidt
Chief Operating Officer
Dr Peter Schmidt holds a Bachelor of Science (Hons) and a PhD in Nuclear Medicine. Dr Schmidt has considerable expertise in the development of drug candidates for submission to both the Therapeutic Goods Administration (TGA) in Australia and the FDA in the USA up to Clinical Phase III including (i) preparation of CMC and Preclinical data packages required for IND submissions, and (ii) the clinical practices required during Clinical Phase I and II trials.
Dr Schmidt’s human development expertise compliments and strengthens QBiotics veterinary drug development team. Dr Schmidt came to QBiotics from the drug discovery and development company Xenome Limited where he was Director of CMC and Preclinical drug development for 6 years. Prior to Xenome, Dr Schmidt was Senior Scientist at Agen Biomedical for 7 years and Professional Officer at Radiopharmaceuticals Australian Nuclear Science and Technology Organisation (ANSTO) for 8 years.